BEIJING, April 21 (Xinhua) -- New Horizon Health, a biotechnology company in China, announced on Tuesday that it completed a round-D financing of 20 million U.S. dollars.
The company stated that it got the investment from investors such as Omniscience Capital, a private investment fund focused on healthcare investment, Exome Asset Management, Qiming Venture Partners, Softbank China Venture Capital (SBCVC), and Duke Management Company.
Up to now, New Horizon Health has gained investments of more than 130 million U.S. dollars. With the injection of the round-D financing, it will further consolidate its position in the domestic early cancer screening field, according to the company.
Jason Li, head of Omniscience, said that China's early cancer screening field is on the eve of the robust development. In particular, the new molecular diagnostic technology based on non-invasive means is a very promising blue ocean market.
New Horizon Health, established in 2013, has medical testing laboratories in Beijing, Hangzhou, and Guangzhou. It has launched home screening products targeting bowel cancer, cervical cancer, gastric cancer, and lung cancer, and serving more than 3 million customers.
Zhu Yeqing, co-founder and CEO of New Horizon Health, said that the company will make its home early cancer screening services penetrate into various scenarios such as medical, health, life, consumption, Internet, etc., through extensive industry cooperation in the next step. (Edited by Hu Pingchao with Xinhua Silk Road, hupingchao@xinhua.org)
A single purchase
